The Onco'Zine Brief
202 FOLLOWERS
The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland, Ph.D., covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as..
The Onco'Zine Brief
4M ago
In this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman.
Dr. Spelman is Vice President and Senior Scientific Director at Be The Match and the Center for International Blood & Marrow Transplant Research (CIBMTR).
Hofland and Spellman talk about the outcomes of a study published in Blood Advances, the journal of the American Society of Hematology. [1] The article discusses the impact of cryopreservation of hematopoietic cell grafts on overall survival (OS) and other outcomes within 1 year after hematopoietic cell transplantation.
At the beginning of the COVID-19 p ..read more
The Onco'Zine Brief
7M ago
In a new episode of The Onco'Zine Brief, Peter Hofland talks with Dr Ely Benaim, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Dr Mark De Souza, President and Chief Executive Officer of SonALAsense.
SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive way to treat and eradicate deadly cancers like High-Grade Gliomas (HGG) that typically require debilitating brain surgery that often leads to tumor recurrence.
Hofland, Benaim and De Souza talk about new technologies in the treatment of diicult to tr ..read more
The Onco'Zine Brief
7M ago
In a new episode of The Onco'Zine Brief, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®
Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.
Hofland and Cognetti talk about new technologies in cell transplats and the importants of people to join and register with Be The Match® as a bone marrow donor to bring hope to people in need ..read more
The Onco'Zine Brief
9M ago
In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer.
First, Hofland talks with Christopher Heery, MD.
Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator, adoptive NK cells, and other therapeutics.
As the chief medical officer at Arcellx, he is respons ..read more
The Onco'Zine Brief
9M ago
In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results.
In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have.
First, Hofland talks with Thomas G. Martin, MD.
Martin is the Associate Director of the University of California San Francisco Myeloma Pr ..read more
The Onco'Zine Brief
1y ago
In this –this episode of the Onco’Zine Brief, Peter Hofland talks with Dr. Matthias Bucerius.
Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates.
Antibody-drug conjugates or ADCs are targeted thera ..read more
The Onco'Zine Brief
1y ago
In this – the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.
In the program today Hofland and Spellman talk about bone-marrow transplants.
The likelihood of finding a fully matched unrelated donor for a patient who needs a bone marrow transplantvaries greatly depending on a patient’s ethnic background, and that ethnically diverse patients have – historically – been at a disadv ..read more
The Onco'Zine Brief
1y ago
In this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities.
An accomplished strategist, she develops and articulates priorities to enhance the V Foundation’s research portfolio, gifts, grants, and sponsorships that advance the V Foundation’s distinctive brand of cutting-edge and disruptive research.
The V Foundation ..read more
The Onco'Zine Brief
1y ago
Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.
In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics.
Olema Terapeutics is developing new treatment options designed to improve outcomes for women with metastatic breast cancer. The company’s lead investigational drug is OP-1250.
This drug is a is a ..read more
The Onco'Zine Brief
1y ago
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. And while the disease can occur at any age, it tends to occur more often in older people.
According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survival after a diagnosis is 15-
18 months, while the disease’s five-year survival rate is around 10%.
And while all glioblastomas recur, initial treatments may keep the tumor controlled
for months or e ..read more